Eric B Haura

US Patent:

20070031871, Feb 8, 2007

Filed:

Jul 20, 2006

Appl. No.:

11/490316

Inventors:

Richard Jove - Glendora CA, US
Susan Minton - Tampa FL, US
Daniel Sullivan - Lutz FL, US
Eric Haura - Tampa FL, US
Gerold Bepler - Tierra Verde FL, US

Assignee:

University of South Florida - Tampa FL

International Classification:

C12Q 1/68
G01N 33/574

US Classification:

435006000, 435007230

Abstract:

Methods are provided for predicting responsiveness of cancer cells to chemotherapy by measuring the level of phosphorylated Stat or the level of expression of Survivin in a cancer and comparing the level in the cancer cell to the respective level in a control. Also provided are methods of selecting a chemotherapeutic treatment for a subject diagnosed with cancer by measuring the level of phosphorylated Stat or the level of expression of Survivin in a cancer and comparing the level in the cancer cell to the respective level in a control. Kits for performing the methods are also provided. Methods for modulating Survivin-dependent apoptosis in a cancer cell are also disclosed.

US Patent:

20070060615, Mar 15, 2007

Filed:

Sep 22, 2006

Appl. No.:

11/534459

Inventors:

William Cress - Lutz FL, US
Eric Haura - Tampa FL, US
Xihong Ma - Tampa FL, US

Assignee:

University of South Florida - Tampa FL

International Classification:

A61K 31/452

US Classification:

514320000

Abstract:

Provided is a method and vector for modulating apoptosis in a target cell population. Flavopiridol treatment leads to apoptosis via a mechanism associated with downregulation of Mcl-1. E2F1 leads to transcriptional repression of Mcl-1 and subsequently apoptosis. Given the ability of cyclin/cyclin-dependent kinase 2 antagonists to kill transformed cells, flavopiridol may stabilize E2F1 and enhance apoptosis via repression of Mcl-1. Flavopiridol is associated with a dose-dependent increase in E2F1 protein levels, a corresponding reduction in Mcl-1, and apoptosis in lung carcinoma cells. Treatment of cells with 200 nM flavopiridol results in the rapid elevation of E2F1 and reduction in Mcl-1 levels within 12 hours of treatment. The elevation of E2F1 and reduction in Mcl-1 clearly precedes the induction of apoptosis. Cell lines that constitutively express Mcl-1 under the control of the cytomegalovirus promoter have no reductions in Mcl-1 levels with flavopiridol treatment and are resistant to apoptosis induced by flavopiridol.

US Patent:

20070213288, Sep 13, 2007

Filed:

Nov 30, 2006

Appl. No.:

11/565287

Inventors:

Eric Haura - Tampa FL, US
Richard Jove - Tampa FL, US
Tammy Bowman - Tampa FL, US
Lanxi Song - Tampa FL, US

Assignee:

UNIVERSITY OF SOUTH FLORIDA - Tampa FL

International Classification:

A61K 31/7052
C07H 21/04

US Classification:

514044000, 536023500

Abstract:

An adenoviral vector which expresses a dominant negative form of Stat3 called Stat3-EVA for the treatment of non-small cell lung carcinoma. This construct has two mutations in the DNA binding site of Stat3 which prevents binding to DNA but has no effect on tyrosine phosphorylation or dimerization.

US Patent:

20100004257, Jan 7, 2010

Filed:

Jul 13, 2009

Appl. No.:

12/501897

Inventors:

Eric Bruce Haura - Tampa FL, US

Assignee:

University of South Floria - Tampa FL

International Classification:

A61K 31/506
A61P 35/00
A61P 35/02

US Classification:

51425219

Abstract:

A method of predicting response to treatment with inhibitors of EGFR and SRC by screening for status of key biomarkers such as EGFR. Dasatinib is a drug that can inhibit a group of proteins called SRC proteins. In addition, other experiments have suggested that other important signaling proteins are affected by dasatinib. Early phase trials of dasatinib are ongoing in cancer patients. It will be important to determine which patients receive a clinical benefit of dasatinib. Predetermination of treatment benefit can be performed by assessing biomarkers in patients tumors prior to treatment with dasatinib or other inhibitors of EGFR and SRC. Patients that have positive biomarkers for treatment could then be treated with higher confidence of benefit while those not possessing these predictive biomarkers would avoid ineffective and potentially toxic therapy. Additionally, treatment can be tailored according to predetermined sensitivity by evaluating indicated biomarkers correlating with sensitivity to one or more agents.

US Patent:

20220257735, Aug 18, 2022

Filed:

Jun 24, 2020

Appl. No.:

17/622375

Inventors:

- Tampa FL, US
Eric B. HAURA - St. Pete Beach FL, US
Scott ANTONIA - Durham NC, US
Chao WANG - Tampa FL, US

International Classification:

A61K 39/00
G01N 33/50

Abstract:

Disclosed are methods for identifying neoantigens and methods of treating cancer using neoantigens identified by said methods. The disclosure herein provide for methods for identifying neoantigens that can be used as a target for the treatment of a cancer, immunize a subject against a cancer, stimulate/induce immune responses, and/or isolate T cells that are reactive to said neoantigens.

US Patent:

20180156798, Jun 7, 2018

Filed:

Oct 28, 2017

Appl. No.:

15/796755

Inventors:

- Tampa FL, US
ERIC B. HAURA - TAMPA FL, US

International Classification:

G01N 33/569
G01N 33/574

Abstract:

The subject invention pertains to materials and methods for the classification of cancers as sensitive or resistant to treatments based on protein-protein interactions, treatment of cancer, identification of biomarkers, identification of protein-protein interaction modulators, and selection of cancer treatments.

US Patent:

20140256649, Sep 11, 2014

Filed:

Sep 27, 2012

Appl. No.:

14/348152

Inventors:

- TAMPA FL, US
Eric B. Haura - Tampa FL, US

International Classification:

G01N 33/569

US Classification:

514 193, 514 44 R, 435 71, 435 721

Abstract:

The subject invention pertains to materials and methods for the classification of cancers as sensitive or resistant to treatments based on protein-protein interactions, treatment of cancer, identification of biomarkers, identification of protein-protein interaction modulators, and selection of cancer treatments.